Psychopharmacology: A Master Class
Carl Salzman, MD
An updated review of neurobiology and brain function, taking the attendee through neurotransmission sequence from synthesis to gene transcription will be provided. Specific categories of treatment will include: schizophrenia, bipolar disorder, depression, anxiety, and sleep disorders. The evidence based effectiveness of conventional antipsychotic medications and atypical antipsychotic medications will be emphasized. Newer, useful agents and augmenting medications for the treatment of psychotic disorders will be discussed. Bipolar disorder and its treatment will be examined with particular reference to bipolar depression. The use of lithium will be emphasized. A comprehensive review of depression in psychiatric patients as well as co-morbid with medical illnesses will be emphasized along with the use of antidepressants of all treatment classes for co-morbid depressions. The role of depression in cardiovascular illness and the necessity for treatment as well as the interaction between endocrine disorders (especially diabetes) and depression will be highlighted. New understanding of the interaction between inflammation and mood disorders will be discussed. Problems with uses of psychiatric medications for the elderly will be discussed with clinical examples. The neurobiological mechanisms of anxiety and anxiety-spectrum disorders as well as their treatment will be reviewed, including obsessive-compulsive disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorder. Data regarding early life traumatic or separation experiences, as precursors to later-life mood disorders will be introduced.
This seminar will address the neurobiological theories of addition and their treatment as well as identifying mechanisms of sleep disorders and their effective psychopharmacologic treatment. Medications for depression in women through the course of their lifecycle will be presented. The potential usefulness of stimulant medications for adults with ADD, binge eating disorders, and treatment resistant depression will be noted. The course will emphasize the establishment and importance of therapeutic alliance when prescribing all psychotropic medications. Educational presentation will be in seminar format and include lectures, participant discussions and Q&A. This seminar is designed for the experienced clinician. Course participants will be expected to have had clinical experience, familiarity with the neurobiological and genetic contributions to psychiatric illnesses as well as an understanding of the basic therapeutic mechanisms of psychotropic medications.
- Apply the latest advances in the neurobiology of psychiatric disorders and the role of genetic testing in the selection of specific psychiatric medications;
- Assess and compare current mechanisms and latest treatment of psychotic disorders, schizophrenia and bipolar illness;
- Analyze and assess the neurobiological mechanism and evidence-based treatment of depression and anxiety and sleep disorders;
- Review latest findings about inflammation and stress as they apply to the treatment of depression and anxiety-spectrum disorders;
- Update the clinical approach to problems in geriatric psychopharmacology with emphasis on newly emerging medication treatment;
- Identify the mechanisms and evidence based treatments of addictive disorders;
- Review the role of psychiatric medications during a women’s life cycle: pregnancy, delivery, post-partum, nursing, and menopause.
- Determine the neurobiological theories of addicts and their treatment;
- Apply an understanding of the biology of sleep disorder for the effective psychopharmacologic treatment of sleep disordert
|Monday, February 27, 2017
9:00 am – 12:15 pm
|An updated and clinically relevant review of neurobiology as it applies to the etiology and pathology of psychiatric illness, and psychotropic drug treatment effects; the neurobiology of “attachment.” Q&A.|
|Tuesday, February 28, 2017
9:00 am – 12:15 pm
|Biology and treatment of psychotic disorders including schizophrenia, bipolar illness, psychotic depression, and psychosis associated with neurologic conditions; current standards of practice; new uses for atypical antipsychotic drugs; special emphasis on evidence-based treatments of bipolar depression; CATIE study and other recent clinical trials of new antipsychotic drugs. Q&A.|
|Wednesday, March 1, 2017
9:00 am – 12:15 pm
|Neurobiological mechanisms of depression and its psychopharmacological treatments, including major depression, bipolar depression, and dysthymia; depression associated with medical illnesses, especially cardiovascular and endocrine disorders; treatments of medically related depressions; STAR*D study and other evidenced based clinical trials. Q&A.|
|Thursday, March 2, 2017
9:00 am – 12:15 pm
|Anxiety and anxiety-spectrum disorders; neurobiological mechanisms of anxiety, and the appropriate role of treatments with benzodiazepines, antidepressants, and new approaches; role of anxiety and stress mechanisms as an etiologic factor in psychiatric illness with suggestions for treatment and prevention. Q&A.|
|Friday, March 3, 2017
9:00 am – 12:15 pm
|Psychotropic drug treatment of psychiatric disorders common in late life; treatment of addictive disorders, and eating disorders; medications for depression for women during pregnancy; presentation of interesting/difficult cases from attendee’s practice for discussion and review. Q&A.|
Beth Israel Deaconess Department of Psychiatry Foundation, Inc./Contact Hours: 15
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Harvard Medical School designates this live activity for a maximum of 15.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Royal College of Physicians and Surgeons of Canada recognizes conferences and workshops held outside of Canada that are developed by a university, academy, hospital, specialty society or college as accredited group learning activities.
Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). Information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
Psychologists: The Continuing Education Program at Beth Israel Deaconess Medical School, a major teaching hospital of Harvard Medical School, is approved by the American Psychological Association to offer Continuing education for psychologists. The Continuing Education Program at Beth Israel Deaconess Medical School, a major teaching hospital of Harvard Medical School, maintains responsibility for this program.
Counselors: The Continuing Education Program at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School, is an NBCC-Approved Continuing Education Provider (ACEPTM) and may offer NBCC-approved clock hours for events that meet NBCC requirements. The ACEPTM solely is responsible for all aspects of the program. The winter seminar programs meet the criteria for 15 clock hours.
Nurses: Applications have been made to the ANA-MA and accredited approver by the American Nurses Credentialing Center Commission on Accreditation.
Social Workers:Applications for social work continuing education credits has been submitted.
Please call Stacy Ruiz at 617-754-1265 or e-mail firstname.lastname@example.org for more information about your credit hours.